DGIdb - ALVOCIDIB Drug Record

ALVOCIDIB chembl:CHEMBL428690 Antineoplastic

Alternate Names:

MDL-107826A
NSC-649890
L-86-8275
L-868275
ALVOCIDIB
HL-275
HMR-1275
FLAVOPIRIDOL
HMR-1274
L 86-8275
ALVOCIDIB FREEBASE
HMR 1275
HL 275
2-(2-CHLOROPHENYL)-5,7-DIHYDROXY-8-[(3S,4R)-3-HYDROXY-1-METHYLPIPERIDIN-4-YL]-4H-CHROMEN-4-ONE
HMR 1274
L 868275
(-)-CIS-5,7-DIHYDROXY-2-(2-CHLOROPHENYL)-8-(4-(3-HYDROXY-1-METHYL)PIPERIDINYL)-4H-1-BENZOPYRAN-4-ONE
L86-8275
chembl:CHEMBL428690
drugbank:03496
chemidplus:146426-40-6
pubchem.compound:5287969

Drug Info:

Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(3 More Sources)

Publications:

Robinson et al., 2003, The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines., Melanoma Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Robey et al., 2001, Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells., Clin. Cancer Res.
Zvelebil, 1998, Flavopiridol Hoechst AG., IDrugs
Witters et al., 2004, Combining flavopiridol with various signal transduction inhibitors., Oncol. Rep.
Smith et al., 2008, Rhabdoid tumor growth is inhibited by flavopiridol., Clin. Cancer Res.
Shao H et al., 2013, Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities., J Med Chem
Montagnoli A et al., 2008, A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity., Nat Chem Biol
Hooijberg et al., 1999, Potent interaction of flavopiridol with MRP1., Br. J. Cancer
Gao et al., 2004, Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol., Mol. Pharmacol.
Motwani et al., 2001, Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts., Clin. Cancer Res.
Kitada et al., 2000, Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia., Blood

ALVOCIDIB CDK3

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
ALVOCIDIB CDK9

Interaction Score: 1.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

Direct Interaction yes

Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs:
11752352 23301767 18469809

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions
ALVOCIDIB CDK6

Interaction Score: 1.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor

Direct Interaction yes

Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs:
11752352

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions
ALVOCIDIB SMARCB1

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
18223228

Sources:
JAX-CKB
ALVOCIDIB CDK7

Interaction Score: 0.9

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 7 inhibitor

Direct Interaction yes

Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs:
18469809 11752352

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions
ALVOCIDIB XIAP

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15235103 11751522 10887097

Sources:
NCI
ALVOCIDIB CDK10

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
ALVOCIDIB CDK4

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

Direct Interaction yes

Novel drug target Novel Target

PMIDs:
11752352

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions
ALVOCIDIB CDK8

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
11752352

Sources:
TdgClinicalTrial
ALVOCIDIB CDKN2A

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
12777976

Sources:
JAX-CKB
ALVOCIDIB CDK1

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name flavopiridol, alvocidib, HMR-1275

Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor

PMIDs:
11752352

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions
ALVOCIDIB CDK2

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor

PMIDs:
18465538 11752352

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions
ALVOCIDIB CDK5

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
11752352

Sources:
MyCancerGenome TdgClinicalTrial
ALVOCIDIB CCND1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ALVOCIDIB ABCC1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10496352

Sources:
NCI
ALVOCIDIB PIK3CB

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14767524

Sources:
NCI
ALVOCIDIB ABCG2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11205902

Sources:
NCI
ALVOCIDIB PIK3CA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14767524

Sources:
NCI

MyCancerGenome: ALVOCIDIB
- Version: 20-Jun-2017
Alternate Names:

HMR-1275 Development Name

FLAVOPIRIDOL Development Name

ALVOCIDIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: ALVOCIDIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

DTC: ALVOCIDIB

Version: 02-September-2020

Alternate Names:

CHEMBL428690 ChEMBL Drug ID

Drug Info:

Publications:

Montagnoli A et al., 2008, A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity., Nat Chem Biol

Shao H et al., 2013, Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities., J Med Chem

NCI: FLAVOPIRIDOL

Version: 14-September-2017

Alternate Names:

C1571 NCI drug code

Drug Info:

Publications:

Hooijberg et al., 1999, Potent interaction of flavopiridol with MRP1., Br. J. Cancer

Robey et al., 2001, Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells., Clin. Cancer Res.

Witters et al., 2004, Combining flavopiridol with various signal transduction inhibitors., Oncol. Rep.

JAX-CKB: Alvocidib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Smith et al., 2008, Rhabdoid tumor growth is inhibited by flavopiridol., Clin. Cancer Res.

Robinson et al., 2003, The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines., Melanoma Res.

ChemblDrugs: chembl:CHEMBL428690
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL428690
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	flavopiridol, alvocidib, HMR-1275
Novel drug target	Novel Target

Mechanism of Interaction	Cyclin-dependent kinase 9 inhibitor
Direct Interaction	yes
Trial Name	flavopiridol, alvocidib, HMR-1275

Mechanism of Interaction	Cyclin-dependent kinase 6 inhibitor
Direct Interaction	yes
Trial Name	flavopiridol, alvocidib, HMR-1275

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

Mechanism of Interaction	Cyclin-dependent kinase 7 inhibitor
Direct Interaction	yes
Trial Name	flavopiridol, alvocidib, HMR-1275

Mechanism of Interaction	Cyclin-dependent kinase 4 inhibitor
Direct Interaction	yes
Novel drug target	Novel Target

HMR-1275	Development Name
FLAVOPIRIDOL	Development Name
ALVOCIDIB	Generic Name

ALVOCIDIB Drug Record

ALVOCIDIB chembl:CHEMBL428690 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name flavopiridol, alvocidib, HMR-1275 Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor Direct Interaction yes Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs: 11752352 23301767 18469809

Sources: DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor Direct Interaction yes Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs: 11752352

Sources: DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 18223228

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 7 inhibitor Direct Interaction yes Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs: 18469809 11752352

Sources: DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15235103 11751522 10887097

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Trial Name flavopiridol, alvocidib, HMR-1275 Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor Direct Interaction yes Novel drug target Novel Target

PMIDs: 11752352

Sources: DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Trial Name flavopiridol, alvocidib, HMR-1275 Novel drug target Novel Target

PMIDs: 11752352

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 12777976

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name flavopiridol, alvocidib, HMR-1275 Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor

PMIDs: 11752352

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name flavopiridol, alvocidib, HMR-1275 Novel drug target Novel Target Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor

PMIDs: 18465538 11752352

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name flavopiridol, alvocidib, HMR-1275 Novel drug target Novel Target

PMIDs: 11752352

Sources: MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10496352

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14767524

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11205902

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14767524

Sources: NCI

MyCancerGenome: ALVOCIDIB

Alternate Names: HMR-1275 Development Name FLAVOPIRIDOL Development Name ALVOCIDIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

Direct Interaction yes

Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs:
11752352 23301767 18469809

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor

Direct Interaction yes

Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs:
11752352

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
18223228

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 7 inhibitor

Direct Interaction yes

Trial Name flavopiridol, alvocidib, HMR-1275

PMIDs:
18469809 11752352

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
15235103 11751522 10887097

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

Direct Interaction yes

Novel drug target Novel Target

PMIDs:
11752352

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
11752352

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
12777976

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name flavopiridol, alvocidib, HMR-1275

Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor

PMIDs:
11752352

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

Mechanism of Interaction Cyclin-dependent kinase 2 inhibitor

PMIDs:
18465538 11752352

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name flavopiridol, alvocidib, HMR-1275

Novel drug target Novel Target

PMIDs:
11752352

Sources:
MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
10496352

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14767524

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11205902

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14767524

Sources:
NCI

Alternate Names:

HMR-1275 Development Name

FLAVOPIRIDOL Development Name

ALVOCIDIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

CHEMBL428690 ChEMBL Drug ID

Alternate Names:

C1571 NCI drug code

Publications:

Smith et al., 2008, Rhabdoid tumor growth is inhibited by flavopiridol., Clin. Cancer Res.

Robinson et al., 2003, The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines., Melanoma Res.